Recent rumours that Biogen was about to acquired by Samsung proved unfounded, but it turns out a deal has been in preparation. The South Korean firm just agreed to buy Biogen out of their ...

Biogen has revealed encouraging phase 2 results with its anti-CD38 antibody felzartamab in rare kidney disease IgA nephropathy (IgAN), which it hopes could join a series of first-in-class ...

After hours: March 21 at 7:27:47 PM EDT Loading Chart for BIIB ...

Biogen Inc是一家全球性生物技术公司。该公司专注于为全球患有严重和复杂疾病的人发现、开发和提供治疗方法。该公司拥有一系列治疗多发性硬化症（MS）、脊髓性肌萎缩症（SMA）和阿尔茨海默病的药物。该公司专注于推进其在神经学、神经精神病学、专业免疫 ...

March 11, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – announced the initiation of dosing in the global clinical study, TRANSCEND. The Phase 3 study will evaluate the efficacy and ...

Antibody-mediated rejection is a significant cause of kidney transplant failure. Credit: sasirin pamai / Shutterstock. US-based biotechnology company Biogen has begun dosing in the Phase III TRANSCEND ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

Biogen Pharmachem Industries Ltd share price was down by -7.48% from the previous closing price of ₹1.07. Who are peers of Biogen Pharmachem Industries Ltd? The peers of Biogen Pharmachem ...

Investors with a lot of money to spend have taken a bullish stance on Biogen BIIB. And retail traders should know. We noticed this today when the trades showed up on publicly available options ...